I am a breastfeeding mother and i want to know if it is safe to use Hydroxycarbamide? Is Hydroxycarbamide safe for nursing mother and child? Does Hydroxycarbamide extracts into breast milk? Does Hydroxycarbamide has any long term or short term side effects on infants? Can Hydroxycarbamide influence milk supply or can Hydroxycarbamide decrease milk supply in lactating mothers?
- DrLact safety Score for Hydroxycarbamide is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of Hydroxycarbamide may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that Hydroxycarbamide may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of Hydroxycarbamide low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using Hydroxycarbamide We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Used for the treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, myeloid leukemia, myeloid splenomegaly), certain cancers and prevention of recurrent painful occlusive crisis in sickle cell anemia from older than 2 years old . It is excreted in breast milk in small amounts, below 10% of relative adult dose or theoretical dose in pediatric patients, so it is not expected the occurrence of side effects on the breastfed infant whose mother is receiving this treatment. Risk may be lowered, especially in infants younger than 3 months, by delaying breastfeeding from 12 to 24 hours after dose.Whenever a long-term treatment is desired monitoring of blood count in the infant should be considered.
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, although the evidence for this recommendation is very weak.[1][2] Although only minimal data are available to determine an appropriate period to withhold breastfeeding, the drug's terminal half-live of 4.5 hours with normal kidney function suggests that withholding breastfeeding for at least 24 hours may be sufficient for patients receiving intermittent therapy. This period may be longer in patients with impaired kidney function. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[3]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.